Cetuximab (C225)
(Synonyms: 西妥昔单抗; C225) 目录号 : GC34217
西妥昔单抗是一种嵌合单克隆抗体，由鼠类抗 EGFR 单克隆抗体 M225 的可变区和人 IgG1 恒定区融合而成。
Cas No.:205923-56-4
Sample solution is provided at 25 µL, 10mM.
Cetuximab is a chimeric monoclonal antibody generated from fusion of the variable region of the murine anti-EGFR monoclonal antibody M225 and the human IgG1 constant region. It produced antibody retains high affinity and specificity to EGFR and reduces immunogenicity.[1] Cetuximab bound with high affinity to FcγRI (EC50 = 0.13 nM) and FcγRIIIa (EC50 = 6 nM). It effectively induced ADCC across multiple tumor cell lines.[4] Treatment with 100?μg/ml cetuximab for 24h enhances the cytotoxicity effect of RSL3 treatment on KRAS mutant CRC cells.[2]
In vitro experiment indicated it that radiation enhances cetuximab (0.5 μg/ml)-mediated ADCC and activation of NK cells.[3] Treatment with 20 μg/mL cetuximab inhibited the proliferation of the parental UMSCC1 cell line (UMSCC1-P) ,while the three HNSCC cetuximab-resistant clones (C2, C5, and C11) were completely refractory to cetuximab.[6]
In vivo experiment it shown that cetuximab (13?mg/kg, s.c.) enhances the inhibitory effects of RSL3 and RSL3-induced ferroptosis.[2] In vivo, after i.v. injection of 4 doses of 10 mg/kg body-weight demonstrated that cetuximab markly inhibited tumor growth in SCC1 tumor bearing mice.[5] In vivo experiment it illustrated that cetuximab-treated (50 mg/kg, i.p.) tumors showed delayed growth, when mice were inoculated with the NSCLC H226 cell line individually with 2x106 tumor cells in the dorsal flank.[6]
References:
[1]. Xiong HQ, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II Trial. J Clin Oncol. 2004 Jul 1;22(13):2610-6.
[2]. Yang J, et al. Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. 2021 Nov 13;12(11):1079.
[3]. Jin WJ, et al. Tumor-Specific Antibody, Cetuximab, Enhances the In Situ Vaccine Effect of Radiation in Immunologically Cold Head and Neck Squamous Cell Carcinoma. Front Immunol. 2020 Nov 12;11:591139.
[4]. Patel D, et al. IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab. Hum Antibodies. 2010;19(4):89-99.
[5]. Niu G, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res. 2010 Apr 1;16(7):2095-105.
[6]. Iida M, et al. Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab. Mol Cancer Ther. 2016 Sep;15(9):2175-86.
西妥昔单抗是一种嵌合单克隆抗体,由鼠类抗 EGFR 单克隆抗体 M225 的可变区和人 IgG1 恒定区融合而成。它产生的抗体对 EGFR 保持高亲和力和特异性并降低免疫原性。[1] Cetuximab 以高亲和力结合 FcγRI (EC50 = 0.13 nM) 和 FcγRIIIa (EC50 = 6 nM)。它有效地诱导多种肿瘤细胞系的ADCC。[4]用100μg/ml西妥昔单抗处理24h增强了RSL3处理对KRAS突变CRC细胞的细胞毒性作用。[2]
体外实验表明,辐射增强了西妥昔单抗（0.5 μg/ml）介导的ADCC和NK细胞的活化。[3]用20 μg/mL西妥昔单抗治疗抑制了亲本细胞的增殖UMSCC1细胞系（UMSCC1-P）,而三个HNSCC西妥昔单抗耐药克隆（C2、C5和C11）对西妥昔单抗完全耐药。[6]
体内实验表明,西妥昔单抗 (13mg/kg, s.c.) 增强了 RSL3 和 RSL3 诱导的铁死亡的抑制作用。[2] 在体内,静脉注射后。注射4次10 mg/kg体重的西妥昔单抗表明西妥昔单抗显着抑制SCC1荷瘤小鼠的肿瘤生长。[5] 体内实验表明西妥昔单抗处理(50 mg/kg, i.p.) 肿瘤显示延迟生长,当小鼠单独接种 NSCLC H226 细胞系时,在背侧有 2x106 个肿瘤细胞。[6]
| Cell experiment [1]: | |
|
Cell lines |
SCC1 and UM-SCC-22B cells |
|
Preparation Method |
The toxicity of cetuximab to SCC1 and UM-SCC-22B cells was determined by MTT assay. At 72 h or 120 h after treatment with different doses of cetuximab (ranging from 0.1 nM to 0.5 μM), the culture medium was replaced and 50 μl of 1.0 mg/ml sterile filtered 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide (MTT; Sigma) was added to each well. |
|
Reaction Conditions |
0.1 nM to 0.5 μM at 72 h or 120 h |
|
Applications |
Treatment with cetuximab produced only modest inhibition of cell proliferation on SCC1 cells in vitro as determined by MMT assay. |
| Animal experiment [2]: | |
|
Animal models |
BALB/c (nu/nu) female nude mice |
|
Preparation Method |
Xenografts were established in female nude mice (BALB c[nu/nu]) by subcutaneous injection of head and neck squamous cell carcinoma cell lines a UT-SCC-14 and b UT-SCC-2. Cetuximab (1 mg/injection) was administered by intraperitoneal injection at day 10, 13 and 16. The tumour size was recorded at an interval of 2–3 days, n = 10-14. |
|
Dosage form |
1 mg, i.p. |
|
Applications |
Cetuximab treatment showed reduction in the nuclear accumulation of HIF-1α, while the overall HIF-1α expression was not significantly altered. And after cetuximab treatment a downregulation of CAIX was only found in UT-SCC-14 xenografts. Cetuximab treatment affects the tumour growth and the tumour partial oxygen pressure as measured by LiPc EPR oximetry. |
|
References: [1]. Niu G, et al. Cetuximab-based immunotherapy and radioimmunotherapy of head and neck squamous cell carcinoma. Clin Cancer Res. 2010 Apr 1;16(7):2095-105. [2]. Gustafsson H, et al. EPR Oximetry of Cetuximab-Treated Head-and-Neck Tumours in a Mouse Model. Cell Biochem Biophys. 2017 Dec;75(3-4):299-309. |
|
| Cas No. | 205923-56-4 | SDF | |
| 别名 | 西妥昔单抗; C225 | ||
| Canonical SMILES | [Cetuximab] | ||
| 分子式 | C6484H10042N1732O2023S36 | 分子量 | 145543.35 |
| 溶解度 | 储存条件 | Store at 4°C, do not freeze | |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.0069 mL | 0.0344 mL | 0.0687 mL |
| 5 mM | 0.0014 mL | 0.0069 mL | 0.0137 mL |
| 10 mM | 0.0007 mL | 0.0034 mL | 0.0069 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
-
Purity: ≥98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet